229 related articles for article (PubMed ID: 37448340)
1. How long should young infants less than two months of age with moderate-mortality-risk signs of possible serious bacterial infection be hospitalised for? Study protocol for a randomised controlled trial from low- and middle-income countries.
PSBI Study Group
J Glob Health; 2023 Jul; 13():04056. PubMed ID: 37448340
[TBL] [Abstract][Full Text] [Related]
2. Optimal place of treatment for young infants aged less than two months with any low-mortality-risk sign of possible serious bacterial infection: Study Protocol for a randomised controlled trial from low- and middle-income countries.
PSBI Study Group
J Glob Health; 2023 Jul; 13():04055. PubMed ID: 37449353
[TBL] [Abstract][Full Text] [Related]
3. Oral amoxicillin plus gentamicin regimens may be superior to the procaine-penicillin plus gentamicin regimens for treatment of young infants with possible serious bacterial infection when referral is not feasible: Pooled analysis from three trials in Africa and Asia.
Longombe AL; Ayede AI; Marete I; Mir F; Ejembi CL; Shahidullah M; Adejuyigbe EA; Wammanda RD; Tshefu A; Esamai F; Zaidi AK; Baqui AH; Cousens S
J Glob Health; 2022 Nov; 12():04084. PubMed ID: 36403158
[TBL] [Abstract][Full Text] [Related]
4. Simplified antibiotic regimens compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised, open-label, equivalence trial.
; Tshefu A; Lokangaka A; Ngaima S; Engmann C; Esamai F; Gisore P; Ayede AI; Falade AG; Adejuyigbe EA; Anyabolu CH; Wammanda RD; Ejembi CL; Ogala WN; Gram L; Cousens S
Lancet; 2015 May; 385(9979):1767-1776. PubMed ID: 25842221
[TBL] [Abstract][Full Text] [Related]
5. Community-based antibiotic delivery for possible serious bacterial infections in neonates in low- and middle-income countries.
Duby J; Lassi ZS; Bhutta ZA
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD007646. PubMed ID: 30970390
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Lessons from implementation research on community management of Possible Serious Bacterial Infection (PSBI) in young infants (0-59 days), when the referral is not feasible in Palwal district of Haryana, India.
Mukhopadhyay R; Arora NK; Sharma PK; Dalpath S; Limbu P; Kataria G; Singh RK; Poluru R; Malik Y; Khera A; Prabhakar PK; Kumar S; Gupta R; Chellani H; Aggarwal KC; Gupta R; Arya S; Aboubaker S; Bahl R; Nisar YB; Qazi SA
PLoS One; 2021; 16(7):e0252700. PubMed ID: 34234352
[TBL] [Abstract][Full Text] [Related]
8. Innovative approach for potential scale-up to jump-start simplified management of sick young infants with possible serious bacterial infection when a referral is not feasible: Findings from implementation research.
Leul A; Hailu T; Abraham L; Bayray A; Terefe W; Godefay H; Fantaye M; Qazi SA; Aboubaker S; Nisar YB; Bahl R; Tekle E; Mulugeta A
PLoS One; 2021; 16(2):e0244192. PubMed ID: 33544712
[TBL] [Abstract][Full Text] [Related]
9. Management of possible serious bacterial infection in young infants where referral is not possible in the context of existing health system structure in Ibadan, South-west Nigeria.
Ayede AI; Ashubu OO; Fowobaje KR; Aboubaker S; Nisar YB; Qazi SA; Bahl R; Falade AG
PLoS One; 2021; 16(3):e0248720. PubMed ID: 33784321
[TBL] [Abstract][Full Text] [Related]
10. Costs and cost-effectiveness of management of possible serious bacterial infections in young infants in outpatient settings when referral to a hospital was not possible: Results from randomized trials in Africa.
Garg CC; Tshefu A; Longombe AL; Kila JN; Esamai F; Gisore P; Ayede AI; Falade AG; Adejuyigbe EA; Anyabolu CH; Wammanda RD; Hyellashelni JD; Yoshida S; Gram L; Nisar YB; Qazi SA; Bahl R
PLoS One; 2021; 16(3):e0247977. PubMed ID: 33720960
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of implementation of simplified management of young infants with possible serious bacterial infection when referral is not feasible in tribal areas of Pune district, Maharashtra, India.
Roy S; Patil R; Apte A; Thibe K; Dhongade A; Pawar B; Nisar YB; Aboubaker S; Qazi SA; Bahl R; Patil A; Juvekar S; Bavdekar A
PLoS One; 2020; 15(8):e0236355. PubMed ID: 32833993
[TBL] [Abstract][Full Text] [Related]
12. Implementation research on management of sick young infants with possible serious bacterial infection when referral is not possible in Jimma Zone, Ethiopia: Challenges and solutions.
Berhane M; Girma T; Tesfaye W; Jibat N; Abera M; Abrahim S; Aboubaker S; Nisar YB; Ahmad Qazi S; Bahl R; Abdissa A
PLoS One; 2021; 16(8):e0255210. PubMed ID: 34370744
[TBL] [Abstract][Full Text] [Related]
13. Simplified antibiotic regimens for treatment of clinical severe infection in the outpatient setting when referral is not possible for young infants in Pakistan (Simplified Antibiotic Therapy Trial [SATT]): a randomised, open-label, equivalence trial.
Mir F; Nisar I; Tikmani SS; Baloch B; Shakoor S; Jehan F; Ahmed I; Cousens S; Zaidi AK
Lancet Glob Health; 2017 Feb; 5(2):e177-e185. PubMed ID: 27988146
[TBL] [Abstract][Full Text] [Related]
14. Oral amoxicillin compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with fast breathing when referral is not possible: a randomised, open-label, equivalence trial.
; Tshefu A; Lokangaka A; Ngaima S; Engmann C; Esamai F; Gisore P; Ayede AI; Falade AG; Adejuyigbe EA; Anyabolu CH; Wammanda RD; Ejembi CL; Ogala WN; Gram L; Cousens S
Lancet; 2015 May; 385(9979):1758-1766. PubMed ID: 25842223
[TBL] [Abstract][Full Text] [Related]
15. Evaluating implementation of "management of Possible Serious Bacterial Infection (PSBI) when referral is not feasible" in primary health care facilities in Sindh province, Pakistan.
Bhura M; Ariff S; Qazi SA; Qazi Z; Ahmed I; Nisar YB; Suhag Z; Soomro AW; Soofi SB
PLoS One; 2020; 15(10):e0240688. PubMed ID: 33052981
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of alternative antibiotic regimens compared with 7 day injectable procaine benzylpenicillin and gentamicin for outpatient treatment of neonates and young infants with clinical signs of severe infection when referral is not possible: a randomised, open-label, equivalence trial.
Baqui AH; Saha SK; Ahmed AS; Shahidullah M; Quasem I; Roth DE; Samsuzzaman AK; Ahmed W; Tabib SM; Mitra DK; Begum N; Islam M; Mahmud A; Rahman MH; Moin MI; Mullany LC; Cousens S; El Arifeen S; Wall S; Brandes N; Santosham M; Black RE;
Lancet Glob Health; 2015 May; 3(5):e279-87. PubMed ID: 25841891
[TBL] [Abstract][Full Text] [Related]
17. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
18. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
[TBL] [Abstract][Full Text] [Related]
19. Simplified antibiotic regimens for young infants with possible serious bacterial infection when the referral is not feasible in the Democratic Republic of the Congo.
Lokangaka A; Ishoso D; Tshefu A; Kalonji M; Takoy P; Kokolomami J; Otomba J; Aboubaker S; Qazi SA; Nisar YB; Bahl R; Bose C; Coppieters Y
PLoS One; 2022; 17(6):e0268277. PubMed ID: 35771738
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
